Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danzhen for Migraine Prophylaxis
NCT02645370Phase 1Unknown
- Sponsor
- Xijing Hospital
- Start
- Feb 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of salvia miltiorrhiza in migraine, sponsored by Xijing Hospital. Primary endpoint: 50% or greater reduction in headache days per month at 3 months. Status: unknown.
02
Drugs
salvia miltiorrhiza
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02645370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02645370.